COST OF CARE COMPARISON OF ELRANATAMAB-BCMM AND TECLISTAMAB-CQYV IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Shah, B. [1 ]
Sandin, R. [2 ]
Liu, Y. [3 ]
Hu, Y. [4 ]
Schepart, A. [5 ]
Hughes, D. [6 ]
Hart, J. [7 ]
Hlavacek, P. [7 ]
机构：
[1] Boston Med Ctr, Boston, MA USA
[2] Pfizer AB, Stockholm, Sweden
[3] Cytel, Rotterdam, Netherlands
[4] Ingress Hlth Cytel Co, Riverside, CA USA
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Dorchester, MA USA
[7] Pfizer Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE14
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
  • [42] Real-World Clinical Outcomes of Teclistamab and Talquetamab in Relapsed/Refractory Multiple Myeloma (RRMM): A UK Single-Centre Experience
    Feixas, Pablo Tenorio
    Cox, Catrin
    Peer, Xavier
    Cuthill, Kirsty
    Benjamin, Reuben
    Gunawan, Arief
    Cuadrado, Maria
    de Farias, Madson Correia
    Jones, John
    Shin, Jin-Sup
    Batool, Asma
    Bowcock, Stella
    Omer, Musab
    Tawde, Prachi
    Bailey, Katharine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S92 - S92
  • [43] MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander
    Raza, Muhammed
    Acosta, Jorge
    Mueller, Patrick Y.
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S187 - S187
  • [44] MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
    Lesokhin, Alexander M.
    Raza, Muhammed Saleem
    Acosta, Jorge
    Muller, Patrick
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    Service, Myeloma
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] ADJUSTED COMPARISON OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE (RWPC) OF THERAPY IN PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mateos, M., V
    Chari, A.
    Usmani, S. Z.
    Goldschmidt, H.
    Weisel, K.
    Qi, K.
    Londhe, A.
    Nair, S.
    Lin, X.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Parekh, T.
    Marshall, A.
    Slavcev, M.
    Moreau, P.
    VALUE IN HEALTH, 2023, 26 (12) : S5 - S5
  • [46] Treatment Patterns and Outcomes Among Patients Who Initiate Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care
    Romanus, Dorothy
    Jhaveri, Mehul
    Labotka, Richard
    Henk, Henry
    Seal, Brian
    BLOOD, 2015, 126 (23)
  • [47] Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Moreau, Philippe
    Usmani, Saad
    van de Donk, Niels W. C. J.
    Garfall, Alfred
    Delforge, Michel
    Oriol, Albert
    Nooka, Ajay
    Rosinol, Laura
    Bahlis, Nizar
    Rodriguez-Otero, Paula
    Martin, Thomas
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Marshall, Alexander
    Slavcev, Mary
    Smit, Jennifer
    Londhe, Anil
    Krishnan, Amrita
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S182
  • [48] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VS BELANTAMAB MAFODOTIN FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Moreau, P.
    Usmani, S. Z.
    van de Donk, N. W. C. J.
    Garfall, A. L.
    Delforge, M.
    Oriol, A.
    Nooka, A.
    Rosinol, L.
    Bahlis, N.
    Rodriguez Otero, P.
    Martin, T. G.
    Diels, J.
    Van Sanden, S.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Marshall, A.
    Slavcev, M.
    Londhe, A.
    Krishnan, A.
    VALUE IN HEALTH, 2023, 26 (12) : S5 - S6
  • [49] Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1
    Tomasson, Michael H.
    Bahlis, Nizar J.
    Costello, Caitlin
    Raje, Noopur S.
    Levy, Moshe Y.
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Damore, Michael A.
    Jiang, Sibo
    Xie, Tao
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Jakubowiak, Andrzej J.
    Gasparetto, Cristina
    Chu, Michael
    Dalovisio, Andrew Peter
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Romanus, Dorothy
    DasMahapatra, Pronabesh
    Hoole, Michael
    Lowe, Maria
    Curran, Chris
    Campbell, Scott
    Bell, Jill A.
    ONCOLOGIST, 2019, 24 (11): : 1479 - 1487
12345